Reslizumab for inadequately controlled asthma with elevated ... | 合法藥品大搜索

Reslizumab is an interleukin-5 antagonist monoclonal antibody. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and ... Read More

What is CINQAIR? CINQAIR is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in people aged 18 years of age ... Read More

由 S Hom 著作 · 2017 · 被引用 18 次 — Reslizumab is an IL-5 antagonist (immunoglobulin G4-kappa). IL-5 is a major cytokine involved in the growth, differentiation, recruitment, activation, and survival of ... Read More

Medscape - Asthma dosing for Cinqair (reslizumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation ... Read More

由 H Ibrahim 著作 · 2019 · 被引用 14 次 — Reslizumab is a humanized monoclonal antibody directed against Interleukin-5. It binds specifically to IL-5 thereby blocking its biological effects ... Read More

由 M Castro 著作 · 2015 · 被引用 874 次 — Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, ... Read More

由 G Brusselle 著作 · 2017 · 被引用 85 次 — Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients ... Read More

Reslizumab is a humanized, IgG4κ monoclonal antibody that inhibits IL-5 binding to the α-subunit of the IL-5 receptor complex on the eosinophil. In contrast to ... Read More

Effect on sputum eosinophils. The effect of reslizumab in patients with asthma and elevated sputum eosinophil counts (at least 3%) was evaluated in a 15-week​, ... Read More